Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P08758
UPID:
ANXA5_HUMAN
Alternative names:
Anchorin CII; Annexin V; Annexin-5; Calphobindin I; Endonexin II; Lipocortin V; Placental anticoagulant protein 4; Placental anticoagulant protein I; Thromboplastin inhibitor; Vascular anticoagulant-alpha
Alternative UPACC:
P08758; D3DNW7; Q6FHB3; Q6FI16; Q8WV69; Q9UDH9
Background:
Annexin A5, known by various names such as Annexin V, Placental anticoagulant protein I, and Vascular anticoagulant-alpha, plays a pivotal role in the blood coagulation cascade. It acts as an indirect inhibitor of the thromboplastin-specific complex, showcasing its anticoagulant properties.
Therapeutic significance:
Given its involvement in recurrent pregnancy loss, a condition marked by spontaneous abortion before 24 weeks of gestation, Annexin A5's study is crucial. Understanding the role of Annexin A5 could open doors to potential therapeutic strategies for managing this pregnancy complication.